These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 10653303

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa.
    Cilia R, Akpalu A, Sarfo FS, Cham M, Amboni M, Cereda E, Fabbri M, Adjei P, Akassi J, Bonetti A, Pezzoli G.
    Brain; 2014 Oct; 137(Pt 10):2731-42. PubMed ID: 25034897
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Force overflow and levodopa-induced dyskinesias in Parkinson's disease.
    Wenzelburger R, Zhang BR, Pohle S, Klebe S, Lorenz D, Herzog J, Wilms H, Deuschl G, Krack P.
    Brain; 2002 Apr; 125(Pt 4):871-9. PubMed ID: 11912119
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Risk and course of motor complications in a population-based incident Parkinson's disease cohort.
    Bjornestad A, Forsaa EB, Pedersen KF, Tysnes OB, Larsen JP, Alves G.
    Parkinsonism Relat Disord; 2016 Jan; 22():48-53. PubMed ID: 26585090
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, PKDS009 Study Group.
    CNS Drugs; 2004 Jan; 18(11):733-46. PubMed ID: 15330687
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Motor complications in an incident Parkinson's disease cohort.
    Scott NW, Macleod AD, Counsell CE.
    Eur J Neurol; 2016 Feb; 23(2):304-12. PubMed ID: 26074125
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Risk of Disabling Response Fluctuations and Dyskinesias for Dopamine Agonists Versus Levodopa in Parkinson's Disease.
    Haaxma CA, Horstink MW, Zijlmans JC, Lemmens WA, Bloem BR, Borm GF.
    J Parkinsons Dis; 2015 Feb; 5(4):847-53. PubMed ID: 26444087
    [Abstract] [Full Text] [Related]

  • 19. [Levodopa-induced dyskinesia in 176 patients with Parkinson's disease].
    Rocha MS, Andrade LA, Ferraz HB, Borges V.
    Arq Neuropsiquiatr; 1995 Dec; 53(4):737-42. PubMed ID: 8729765
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.